PTC Therapeutics Inc
PTCT71.770USD
+4.050+5.98%
收盘 11/05, 16:00（美东）报价延迟15分钟
5.74B总市值
9.12市盈率 TTM
关于 PTC Therapeutics Inc 公司
PTC Therapeutics, Inc. 是一家全球性生物制药公司。该公司专注于发现、开发和商业化临床差异化药物，为罕见疾病患者带来益处。该公司拥有多元化的治疗产品组合，包括处于不同开发阶段的多种商业产品和候选产品，包括发现、研究和临床阶段，专注于开发与神经病学和代谢相关的罕见疾病的多个治疗领域的新疗法。该公司有两种产品，Translarna (ataluren) 和 Emflaza (deflazacort)，用于治疗杜氏肌营养不良症 (DMD)，这是一种罕见的危及生命的疾病。其 Upstaza 是一种基因疗法，用于治疗芳香族 L-氨基脱羧酶 (AADC) 缺乏症，这是一种罕见的中枢神经系统 (CNS) 疾病。其 Tegsedi 和 Waylivra 用于治疗罕见疾病。其 Evrysdi 是一种脊髓性肌萎缩症 (SMA) 的治疗方法。
PTC Therapeutics Inc简介
公司代码PTCT
公司名称PTC Therapeutics Inc
上市日期Jun 20, 2013
CEODr. Matthew B. Klein, M.D.
员工数量939
证券类型Ordinary Share
年结日Jun 20
公司地址500 Warren Corporate Center Drive
城市WARREN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编07059
电话19082227000
网址https://www.ptcbio.com/
公司代码PTCT
上市日期Jun 20, 2013
CEODr. Matthew B. Klein, M.D.
PTC Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
151.94K
+73.29%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
16.17K
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
16.17K
+2.10%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
6.53K
+5.37%
Ms. Emma Reeve
Ms. Emma Reeve
Independent Director
Independent Director
4.33K
-45.83%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
151.94K
+73.29%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
413.04M
51.20%
Non-US
393.74M
48.80%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.43%
RTW Investments L.P.
9.75%
BlackRock Institutional Trust Company, N.A.
7.29%
Armistice Capital LLC
5.96%
Wellington Management Company, LLP
5.91%
其他
60.66%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.43%
RTW Investments L.P.
9.75%
BlackRock Institutional Trust Company, N.A.
7.29%
Armistice Capital LLC
5.96%
Wellington Management Company, LLP
5.91%
其他
60.66%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
41.35%
Investment Advisor
34.02%
Hedge Fund
16.93%
Research Firm
6.79%
Corporation
1.75%
Individual Investor
0.78%
Pension Fund
0.71%
Venture Capital
0.47%
Bank and Trust
0.34%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
547
79.99M
100.70%
-9.69M
2025Q2
548
83.85M
105.78%
-6.53M
2025Q1
551
82.28M
103.88%
-8.58M
2024Q4
513
80.63M
102.26%
-7.88M
2024Q3
503
82.04M
106.59%
-9.34M
2024Q2
498
82.97M
107.86%
-13.36M
2024Q1
493
89.17M
116.42%
-6.48M
2023Q4
485
88.17M
116.52%
-2.91M
2023Q3
477
85.04M
112.75%
-2.96M
2023Q2
478
84.63M
112.42%
-161.84K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
8.83M
11.11%
+236.45K
+2.75%
Jun 30, 2025
RTW Investments L.P.
7.75M
9.75%
+263.29K
+3.52%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.79M
7.29%
-157.94K
-2.66%
Jun 30, 2025
Armistice Capital LLC
4.74M
5.96%
-699.38K
-12.87%
Jun 30, 2025
Wellington Management Company, LLP
4.69M
5.91%
-725.03K
-13.38%
Jun 30, 2025
Janus Henderson Investors
3.18M
4%
+258.29K
+8.86%
Jun 30, 2025
State Street Investment Management (US)
3.00M
3.77%
+541.56K
+22.06%
Jun 30, 2025
TD Securities, Inc.
2.45M
3.08%
-167.24K
-6.40%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.44M
3.07%
+992.42K
+68.67%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.44%
+60.71K
+3.24%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.45%
Invesco Biotechnology & Genome ETF
3.32%
ALPS Medical Breakthroughs ETF
2.79%
Harbor Human Capital Factor US Small Cap ETF
2.17%
Virtus LifeSci Biotech Products ETF
2%
Euclidean Fundamental Value ETF
1.88%
First Trust NASDAQ Pharmaceuticals ETF
1.61%
Invesco Dorsey Wright Healthcare Momentum ETF
1.6%
SPDR S&P Biotech ETF
1.59%
Global X Guru Index ETF
1.54%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.45%
Invesco Biotechnology & Genome ETF
占比3.32%
ALPS Medical Breakthroughs ETF
占比2.79%
Harbor Human Capital Factor US Small Cap ETF
占比2.17%
Virtus LifeSci Biotech Products ETF
占比2%
Euclidean Fundamental Value ETF
占比1.88%
First Trust NASDAQ Pharmaceuticals ETF
占比1.61%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.6%
SPDR S&P Biotech ETF
占比1.59%
Global X Guru Index ETF
占比1.54%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
